Life Extension Research: Healthspan, Not Immortality Marketing

Republican health rhetoric in 2025-2026 has emphasized chronic illness, deregulation, and faster innovation. The clearest legislative anchor is House Republicans' 2024 NIH restructuring blueprint, led by then-Energy and Commerce Chair Cathy McMorris Rodgers, which would fold ARPA-H, NCATS, NIBIB, and the Common Fund into a single "National Institute on Innovation and Advanced Research" alongside an overall funding reduction; House Appropriations Chair Rosa DeLauro's objection was not to consolidation itself but that the process moved without the bipartisan hearings a restructuring this size should get. Democratic health rhetoric more often emphasizes preserving NIH's existing institute structure, funding levels, public health, coverage, and drug affordability. Neither major party's mainstream platform has made healthspan endpoints, geroscience, fraud enforcement, and equitable translation a coherent policy lane on its own. The clearest point of emerging convergence is procedural, not partisan: Rep. Jake Auchincloss's 2026 clinical-trial-modernization discussion draft, framed from the outset to attract cross-party support, would have FDA embed reusable trial networks into routine care and modernize IRB oversight, which is close to the faster, rigorous trial design this issue's healthspan agenda depends on. The Innovation Party's delta is to be more open to ambitious aging biology than either party's institutional caution, and more evidence-bound than the anti-aging market that surrounds it.